KLRS
Kalaris Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$3.90
−1.02%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +40.4%
- EBIT
- +40.3%
- EPS
- +86.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -2.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +28.6%
- EBIT
- +16.5%
- Net income
- +26.1%
- EPS
- +75.7%
- Free cash flow
- +36.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026